A patient taking an experimental cancer drug from Kite Pharma died after experiencing severe brain swelling, the company said Monday.
The news sparked alarm on the heels of a series of patient deaths at competitor Juno Therapeutics, which is developing the same type of cutting-edge cancer immunotherapy, called CAR-T. The report may raise caution about the immunotherapy drugs that have sparked sky-high hopes even as their downsides have become increasingly apparent.
About the Author Reprints
